201 related articles for article (PubMed ID: 21745000)
1. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Zeng HZ; Qu YQ; Liang AB; Deng AM; Zhang WJ; Xiu B; Wang H; Wang H
Neoplasma; 2011; 58(5):449-54. PubMed ID: 21745000
[TBL] [Abstract][Full Text] [Related]
2. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Li CH; Liu MY; Liu W; Li DD; Cai L
Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
[TBL] [Abstract][Full Text] [Related]
3. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
Rosati G; Rossi A; Nicolella G; Panza N
Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183
[TBL] [Abstract][Full Text] [Related]
5. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Ann Oncol; 2010 Sep; 21(9):1817-1824. PubMed ID: 20332140
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Hasturk S; Hatabay N; Ece F; Karatasli M; Hanta I
Am J Clin Oncol; 2009 Jun; 32(3):280-5. PubMed ID: 19433960
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Vansteenkiste J; Barlesi F; Waller CF; Bennouna J; Gridelli C; Goekkurt E; Verhoeven D; Szczesna A; Feurer M; Milanowski J; Germonpre P; Lena H; Atanackovic D; Krzakowski M; Hicking C; Straub J; Picard M; Schuette W; O'Byrne K
Ann Oncol; 2015 Aug; 26(8):1734-40. PubMed ID: 25939894
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
13. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
14. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
18. Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Dongiovanni D; Fissore C; Berruti A; Buffoni L; Addeo A; Barone C; Polimeni MA; Ottaviani D; Bertetto O; Dongiovanni V
Lung Cancer; 2005 Feb; 47(2):269-75. PubMed ID: 15639726
[TBL] [Abstract][Full Text] [Related]
19. A landmark point analysis with cytotoxic agents for advanced NSCLC.
Yamamoto N; Nambu Y; Fujimoto T; Koshiji M
J Thorac Oncol; 2009 Jun; 4(6):697-701. PubMed ID: 19318995
[TBL] [Abstract][Full Text] [Related]
20. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]